Showing results (1-10 of 66) with videos related to
Sort By:
Pageof 7
Expert Opinion on Investigational Drugs|June 24, 2004
Targeting Syk as a treatment for allergic and autoimmune disordersBrian R Wong, Elliott B Grossbard, Donald G Payan, et al.ACS Medicinal Chemistry Letters|April 22, 2022
Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 InhibitorsYan Chen, Rajinder Singh, Nan Lin, et al.ACS Medicinal Chemistry Letters|November 17, 2022
Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical CandidateYan Chen, Hui Li, Rose Yen, et al.Bioorganic & Medicinal Chemistry Letters|July 21, 2022
Bicyclic pyrimidine compounds as potent IRAK4 inhibitorsYan Chen, Kin Tso, Thilo J Heckrodt, et al.The Journal of Allergy and Clinical Immunology|September 5, 2006
Identification of the Syk kinase inhibitor R112 by a human mast cell screenAlexander B Rossi, Ellen Herlaar, Sylvia Braselmann, et al.Pulmonary Pharmacology & Therapeutics|August 3, 2007
Syk inhibitors as treatment for allergic rhinitisEsteban S Masuda, Jochen SchmitzBioorganic & Medicinal Chemistry Letters|April 16, 2015
Application of cultured human mast cells (CHMC) for the design and structure-activity relationship of IgE-mediated mast cell activation inhibitorsAnkush Argade, Somasekhar Bhamidipati, Hui Li, et al.Chemistry & Biology|October 27, 2007
A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1Tarikere L Gururaja, Stephanie Yung, Rongxian Ding, et al.International Journal of Hematology|March 2, 2010
The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseasesYasumichi Hitoshi, Nan Lin, Donald G Payan, et al.Biopolymers|November 9, 2006
Gas phase dimerization of neuropeptide head activator analogs useful for the noncovalent constraint of peptidesTarikere L Gururaja, Donald G Payan, D C AndersonPageof 7